UHMS Reference Material
UHMS Reference Material
Richard E. Moon MD
Chair and Editor
All rights reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form
or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the
publisher.
ISBN: 978-1-947239-16-6
PART I. Indications
1. Hyperbaric Treatment of Air or Gas Embolism: Current Recommendations . . . . . . . 1
2. Arterial Insufficiencies
A. Central Retinal Artery Occlusion . . . . . . . . . . . . . . . . . . . . . . 15
B. Hyperbaric Oxygen Therapy for Selected Problem Wounds . . . . . . . . . . . . 31
3. Carbon Monoxide Poisoning. . . . . . . . . . . . . . . . . . . . . . . . . 81
4. Clostridial Myonecrosis (Gas Gangrene) . . . . . . . . . . . . . . . . . . . . 105
5. The Effect of Hyperbaric Oxygen on Compromised Grafts and Flaps. . . . . . . . . 117
6. The Role of Hyperbaric Oxygen for Acute Traumatic Ischemias. . . . . . . . . . . 135
7. Decompression Sickness. . . . . . . . . . . . . . . . . . . . . . . . . . 153
8. Delayed Radiation Injuries (Soft Tissue and Bony Necrosis)
and Potential for Future Research. . . . . . . . . . . . . . . . . . . . . . 163
9. Sudden Sensorineural Hearing Loss. . . . . . . . . . . . . . . . . . . . . . 203
10. Intracranial Abscess . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
11. Necrotizing Soft Tissue Infections . . . . . . . . . . . . . . . . . . . . . . 239
12. Refractory Osteomyelitis . . . . . . . . . . . . . . . . . . . . . . . . . . 263
13. Severe Anemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293
14. Adjunctive Hyperbaric Oxygen Therapy in the Treatment of Thermal Burns. . . . . . 301
Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
Preface
The application of air under pressure (hyperbaric air) dates back to 1667, when Nathaniel Henshaw proposed a
hypo-hyperbaric room pressurized and depressurized with an organ bellows.1 In the nineteenth century, Simpson
wrote a treatise on the use of compressed air for certain respiratory diseases.2 The medicinal uses of oxygen were
first reported by Beddoes in 1794,3 while the first article describing adjunctive uses of hyperbaric oxygen therapy
(HBO2) was written by Fontaine in 1879,4 who constructed a mobile operating room which could be pressur-
ized. He observed that pressurized patients were not as cyanotic after the use of nitrous oxide during induction
of anesthesia as compared to patients anesthetized at atmospheric pressure. In addition, he noted that hernias
were much easier to reduce. Also around that time, the work of Paul Bert5 and J. Lorrain-Smith6 showed that oxy-
gen under pressure had potentially deleterious consequences on the human body with side effects that included
central nervous system and pulmonary toxicity. The efforts of Churchill-Davidson and Boerema in the 1950s and
1960s spurred the modern scientific use of clinical hyperbaric medicine.
In 1967, the Undersea Medical Society was founded by six United States Naval diving and submarine medical
officers with the explicit goal of promoting diving and undersea medicine. In short order, this society expanded
to include those interested in clinical hyperbaric medicine. In recognition of the dual interest by members in both
diving and clinical applications of compression therapy, the society was renamed The Undersea and Hyperbaric
Medical Society in 1986. It remains the leading not for profit organization dedicated to reporting scientifically
and medically efficacious and relevant information pertaining to hyperbaric and undersea medicine.
In 1972, an ad hoc Medicare committee was formed to evaluate the efficacy of hyperbaric oxygen therapy for
specified medical conditions. The focus was to determine if this treatment modality showed therapeutic benefit
and merited insurance coverage. The growth of the body of scientific evidence that had developed over the pre-
ceding years supported this endeavor and recognition for the field. In 1976, the Hyperbaric Oxygen Therapy
Committee became a standing committee of what was then the UMS. The first Hyperbaric Oxygen Committee
Report was published in 1977 and served as guidance for practitioners and scientists interested in HBO2. The
report is usually published every three to five years and was last published in 2014. Additionally, this document
continues to be used by the Centers for Medicare and Medicaid Services and other third party insurance carriers
in determining payment.
The report, currently in its 14th edition, has grown in size and depth to reflect the evolution of the literature. To
date, the committee recognizes 14 indications for which scientific and clinical evidence supports the use of HBO2.
The Undersea and Hyperbaric Medical Society continues to maintain its reputation for its expertise on hyper-
baric therapy. With leading experts authoring chapters in their respective fields, this publication continues to
provide the most current and up to date guidance and support for scientists and practitioners of hyperbaric
oxygen therapy.
Richard E. Moon MD
Editor, UHMS Committee Chair
Dirk Bakker MD
Robert Barnes MD
Michael Bennett MD
Enrico Camporesi MD
Paul Cianci MD
James Clark MD
William Dodson, MD
John Feldmeier DO
Laurie Gesell MD
Neil B. Hampson MD
Brett Hart MD
Enoch Huang MD
Irving Jacoby MD
Robert Marx DDS
Heather Murphy-Lavoie MD
Richard Roller MD
Ben Slade MD
Michael Strauss MD
Stephen Thom MD, PhD
Keith Van Meter MD
Lindell Weaver MD
Wilbur T. Workman MS
vii
The Undersea and Hyperbaric Medical Society (UHMS) is an international scientific organization which was
founded in 1967 to foster exchange of data on the physiology and medicine of commercial and military diving.
Over the intervening years, the interests of the Society have enlarged to include clinical hyperbaric oxygen therapy.
The society has grown to over 2,000 members and has established the largest repository of diving and hyperbaric
research collected in one place. Clinical information, an extensive bibliographic database of thousands of scientific
papers, as well as books, and technical reports which represent the results of over 100 years of research by military
and university laboratories around the world are contained in the UHMS Schilling Library, holdings are now part
of the Duke University Library, Durham, NC. The results of ongoing research and clinical aspects of undersea and
hyperbaric medicine are reported annually at scientific meetings and in Undersea and Hyperbaric Medicine published
bi-monthly. Previously the society supported two journals, Undersea Biomedical Research and the Journal of Hyper-
baric Medicine. These two journals were merged in 1993 into Undersea and Hyperbaric Medicine.
I. Background ~ ix
The UHMS defines hyperbaric oxygen (HBO2) as an intervention in which an individual breathes near 100%
oxygen intermittently while inside a hyperbaric chamber that is pressurized to greater than sea level pressure (1
atmosphere absolute [ATA]). For clinical purposes, the pressure must equal or exceed 1.4 ATA while breathing
near 100% oxygen. The United States Pharmacopoeia (USP) and Compressed Gas Association (CGA) Grade A
specify medical grade oxygen to be not less than 99.0% by volume, and the National Fire Protection Association
(NFPA) specifies USP medical grade oxygen.
According to the UHMS definition and the determination of The Centers for Medicare and Medicaid Services
(CMS) and other third-party carriers, breathing medical grade near-100% oxygen at 1 atmosphere of pressure or
exposing isolated parts of the body to 100% oxygen does not constitute HBO2 therapy. The patient must receive
the oxygen by inhalation within a pressurized chamber. Current information indicates that pressurization should
be to 1.4 ATA or higher.
The literature of HBO2 treatment began to appear during the 1930s as navies and universities around the world
began studies in oxygen breathing at elevated pressures as a way to more safely decompress divers and to treat
decompression sickness and arterial gas embolism. During the 1960s, HBO2 was incorporated in standard treat-
ment tables of the U.S. Navy. Extensive research on oxygen toxicity was undertaken to establish safe limits,
overall safety, and medical and physiologic aspects of the compressed gas environment. These efforts led to a vast
body of literature which underpins modern HBO2 therapy.
In 1976, recognizing the need for meticulous scrutiny of emerging clinical applications of HBO2, the Executive
Committee of the UHMS established the Hyperbaric Oxygen Therapy Committee. The Committee was charged
with the responsibility of continuously reviewing research and clinical data and rendering recommendations
regarding clinical efficacy and safety of HBO2. To achieve this goal, the multispecialty committee is comprised
of practitioners and scientific investigators in the fields of internal medicine, infectious diseases, pharmacology,
emergency medicine, general surgery, orthopedic surgery, trauma surgery, thoracic surgery, otolaryngology, oral
and maxillofacial surgery, anesthesiology, pulmonology, critical care, radiation oncology and aerospace medicine.
Since 1976, the Committee has met annually to review research and clinical data. From the 28 indications for
which third-party reimbursement was recommended in the 1976 and 1979 reports, the number of recognized
indications has been refined to 14 in the current report. These indications are those for which in vitro and in
vivo pre-clinical research data as well as extensive positive clinical experience and study have become convincing.
Evidence considered by the Committee includes sound physiologic rationale; in vivo or in vitro studies that
demonstrate effectiveness; controlled animal studies, prospective controlled clinical studies; and extensive clinical
experience from multiple, recognized hyperbaric medicine centers.
The Committee requires that experimental and clinical evidence submitted for the efficacy of HBO2 treatment
for a disorder be at least as convincing as that for any other currently accepted treatment modality for that dis-
order. Studies in progress will continue to clarify mechanisms of action, optimal oxygen dosage, duration of
exposure times, frequency of treatments, and patient selection criteria. The Committee recommends third party
reimbursement of HBO2 therapy for the disorders included in the accepted conditions category. Currently, most
insurance carriers have established HBO2 reimbursement policies.
The Committee also reviews cost effectiveness and has established guidelines for each entity. Results show that, in
addition to its clinical efficacy, HBO2 therapy yields direct cost savings by successfully resolving a high percent-
age of difficult and expensive disorders, thereby minimizing prolonged hospitalization. However, the Committee
recommends that each individual hyperbaric facility, whether monoplace or multiplace, establish its own charges
consistent with the actual local costs of providing such service.
A utilization review section is presented for each recognized HBO2 indication. It is recommended that utilization
review be obtained if the number of HBO2 treatments is to exceed the recommended number of treatments for
that indication. Such review should involve discussion of the clinical case with another qualified hyperbaric medi-
cine physician from an outside institution. If that individual agrees that additional HBO2 therapy is warranted,
treatment may exceed the usually prescribed number of treatments.
New indications for HBO2 therapy are considered for acceptance at the meeting of the Hyperbaric Oxygen
Therapy Committee during the annual meeting of the Undersea and Hyperbaric Medical Society. This consid-
eration can be initiated from within the Committee itself or may result in response to a written request by a
non-Committee member. When a new indication is considered for acceptance, a position paper is written. The
information must summarize the in vitro, in vivo, and clinical aspects of the new indication for HBO2 therapy.
Two members of the Hyperbaric Oxygen Committee review the position paper and each writes a critique. The
position paper and critiques are presented to the Hyperbaric Oxygen Committee. A consensus of the Hyperbaric
Oxygen Committee is required for recommending the indication be moved into the recognized category. If the
Committee determines that a new condition merits acceptance, it makes this recommendation to the Executive
Committee of the Society, which ultimately votes whether or not to recognize the new indication.
REFERENCES
1. Hunt TK, Ellison EC, Sen CK. Oxygen: at the foundation of wound healing--introduction. World J Surg.
2004;28(3):291-293.
2. Janis JE, Harrison B. Wound healing: part I. Basic science. Plast Reconstr Surg. 2014;133(2):199e-207e.
3. Sen CK. Wound healing essentials: let there be oxygen. Wound Repair Regen. 2009;17(1):1-18.
4. Allen DB, Maguire JJ, Mahdavian M, et al. Wound hypoxia and acidosis limit neutrophil bacterial killing
mechanisms. Arch Surg. 1997;132(9):991-996.
5. Hunt TK, Pai MP. The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. Surg
Gynecol Obstet. 1972;135(4):561-567.
6. Hopf HW, Gibson JJ, Angeles AP, et al. Hyperoxia and angiogenesis. Wound Repair Regen. 2005;13(6):558-564.
7. Knighton DR, Silver IA, Hunt TK. Regulation of wound-healing angiogenesis-effect of oxygen gradients and
inspired oxygen concentration. Surgery. 1981;90(2):262-270.
8. LaVan FB, Hunt TK. Oxygen and wound healing. Clin Plast Surg. 1990;17(3):463-472.
9. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ. Oxygen tension regulates the
expression of angiogenesis factor by macrophages. Science. 1983;221(4617):1283-1285.
10. Knighton DR, Fiegel VD, Halverson T, Schneider S, Brown T, Wells CL. Oxygen as an antibiotic. The effect of
inspired oxygen on bacterial clearance. Arch Surg. 1990;125(1):97-100.
11. Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic. The effect of inspired oxygen on infection. Arch
Surg. 1984;119(2):199-204.
12. Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic. A comparison of the effects of inspired oxygen
concentration and antibiotic administration on in vivo bacterial clearance. Arch Surg. 1986;121(2):191-195.
13. Ruthenborg RJ, Ban JJ, Wazir A, Takeda N, Kim JW. Regulation of wound healing and fibrosis by hypoxia and
hypoxia-inducible factor-1. Mol Cells. 2014;37(9):637-643.
14. UHMS Position Statement: Topical Oxygen for Chronic Wounds. Undersea Hyperb Med. 2018;45(3):379-380.
15. Heughan C, Grislis G, Hunt TK. The effect of anemia on wound healing. Ann Surg. 1974;179(2):163-167.
16. Knighton DR, Fiegel VD. Macrophage-derived growth factors in wound healing: regulation of growth factor
production by the oxygen microenvironment. Am Rev Respir Dis. 1989;140(4):1108-1111.
17. Hunt TK, Aslam RS. Oxygen 2002: wounds. Undersea Hyperb Med. 2004;31(1):147-153.
18. Hohn DC. Leukocyte phagocytic function and dysfunction. Surg Gynecol Obstet. 1977;144(1):99-104.
19. Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). N Engl J Med.
1978;298(12):659-668.
20. Babior BM. The respiratory burst of phagocytes. J Clin Invest. 1984;73(3):599-601.
21. Tizard J. Destruction of foreign material - the myeloid system, neutrophils. In: Immunology: an introduction. 3rd
ed. Forth Worth, TX: Saunders College Publishing; 1992.
22. Silver IA. Tissue PO2 changes in acute inflammation. Adv Exp Med Biol. 1978;94:769-774.
23. Hohn DC, MacKay RD, Halliday B, Hunt TK. Effect of O2 tension on microbicidal function of leukocytes in
wounds and in vitro. Surg Forum. 1976;27(62):18-20.
24. Niinikoski J. Effect of oxygen supply on wound healing and formation of experimental granulation tissue. Acta
Physiol Scand Suppl. 1969;334:1-72.
25. Pai MP, Hunt TK. Effect of varying oxygen tensions on healing of open wounds. Surg Gynecol Obstet.
1972;135(5):756-758.
26. Kivisaari J, Vihersaari T, Renvall S, Niinikoski J. Energy metabolism of experimental wounds at various oxygen
environments. Ann Surg. 1975;181(6):823-828.
27. Chang N, Goodson WH, 3rd, Gottrup F, Hunt TK. Direct measurement of wound and tissue oxygen tension in
postoperative patients. Ann Surg. 1983;197(4):470-478.
28. Bullough WS, Johnson M. Epidermal mitotic activity and oxygen tension. Nature. 1957;167:488.
29. Udenfriend S. Formation of hydroxyproline in collagen. Science. 1966;152:1335.
30. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by
stimulation of bone marrow-derived progenitor cell mobilization and homing. J Vasc Surg. 2007;45 Suppl A:A39-47.
31. Thom SR, Milovanova TN, Yang M, et al. Vasculogenic stem cell mobilization and wound recruitment in diabetic
patients: increased cell number and intracellular regulatory protein content associated with hyperbaric oxygen
therapy. Wound Repair Regen. 2011;19(2):149-161.
32. Winter G, Perrins D. Effects of hyperbaric oxygen treatment on epidermal regeneration. Paper presented at: Fourth
International Congress on Hyperbaric Medicine 1970; Tokyo.